JNJ-54175446 explained

JNJ-54175446 is an investigational P2X7 receptor antagonist developed by Janssen Pharmaceuticals. It is hoped that the drug can reduce neuroinflammation and therefore treat psychiatric disorders such as major depressive disorder.[1] [2] [3] [4] [5] [6]

See also

Notes and References

  1. Recourt . Kasper . van der Aart . Jasper . Jacobs . Gabriel . de Kam . Marieke . Drevets . Wayne . van Nueten . Luc . Kanhai . Kawita . Siebenga . Pieter . Zuiker . Rob . Ravenstijn . Paulien . Timmers . Maarten . van Gerven . Joop . de Boer . Peter . Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial . Journal of Psychopharmacology . September 2020 . 34 . 9 . 1030–1042 . 10.1177/0269881120914206. 32248747 . 214809417 .
  2. Timmers . Maarten . Ravenstijn . Paulien . Xi . Liwen . Triana-Baltzer . Gallen . Furey . Maura . Van Hemelryck . Sandy . Biewenga . Jeike . Ceusters . Marc . Bhattacharya . Anindya . van den Boer . Maarten . van Nueten . Luc . de Boer . Peter . Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants . Journal of Psychopharmacology . December 2018 . 32 . 12 . 1341–1350 . 10.1177/0269881118800067. 30260294 . 52842478 .
  3. Bhattacharya . Anindya . Ceusters . Marc . Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders . Neuropsychopharmacology . January 2020 . 45 . 1 . 234–235 . 10.1038/s41386-019-0502-9 . 31477815 . 6879571 . 0893-133X.
  4. Recourt . Kasper . de Boer . Peter . van der Ark . Peter . Benes . Heike . van Gerven . Joop M. A. . Ceusters . Marc . van Nueten . Luc . Drevets . Wayne C. . Bhatacharya . Anindya . Browning . Michael . Jacobs . Gabriel E. . Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder . Translational Psychiatry . 24 July 2023 . 13 . 1 . 1–11 . 10.1038/s41398-023-02557-5 . 37482560 . 260114192 . en . 2158-3188. free . 10363543 .
  5. Koole . Michel . Schmidt . Mark E. . Hijzen . Anja . Ravenstijn . Paulien . Vandermeulen . Corinne . Van Weehaeghe . Donatienne . Serdons . Kim . Celen . Sofie . Bormans . Guy . Ceusters . Marc . Zhang . Wei . Van Nueten . Luc . Kolb . Hartmuth . de Hoon . Jan . Van Laere . Koen . 18 F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446 . Journal of Nuclear Medicine . May 2019 . 60 . 5 . 683–690 . 10.2967/jnumed.118.216747. 30262518 . 52880797 . free .
  6. Xu . Yan . Miao . Xin . Ravenstijn . Paulien . Hijzen . Anja . Schmidt . Mark E. . Nandy . Partha . Zhou . Honghui . Translational Model‐Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ‐54175446, a P2X7 Receptor Antagonist . Clinical and Translational Science . March 2020 . 13 . 2 . 309–317 . 10.1111/cts.12711. 31642608 . 204850939 . free . 7070800 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "JNJ-54175446".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.